Based on emerging knowledge of the HER2-signaling pathways and of signaling through alternative pathways, several drugs against HER2-overexpressing breast cancers are in different phases of clinical development, whereas others are still struggling to leave the bench. Here, ERBB2 is linked to breast carcinoma.